Miragen Therapeutics this week announced the publication of preclinical data showing that a specific microRNA, miR-15, is up-regulated in response to ischemic damage in two model systems.
The data also show that the miRNA contributes to cardiovascular diseases by regulating heart muscle cell death after a heart attack, the company said.
The miRNA is currently the target of a Miragen drug-development program in post-myocardial infarction remodeling. It is covered under Miragen's recent partnership with France's Les Laboratoires Servier (GSN 10/20/2011).
"These findings represent an important step toward optimization of oligonucleotide-based therapies for modulation of cardiac miRNAs," Eric Olson, a researcher at the University of Texas Southwestern Medical Center and Miragen co-founder, said in a statement. “Importantly, this study validates miR-15 as a therapeutic target for the manipulation of cardiac remodeling and function in the setting of ischemic heart disease."
The data appeared in the online edition of Circulation Research.